ReviewOncotarget2017
Molecular markers of paragangliomas/pheochromocytomas.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Immunohistochemistry and Mutation Analysis ofInternational journal of molecular sciences · 2020Trial
- Hypercobalaminemia Leading to the Diagnosis of Retroperitoneal Paraganglioma: A Case Report.Cureus · 2026Article
- ROSBASE1.0: a comprehensive database of reactive oxygen species (ROS): categorization of cell organelles, proteins, taxonomy, and diseases based on ROS-related activities.Database : the journal of biological databases and curation · 2025Article
- A Rare Case of a Middle Mediastinal Mass With Intense and Diffuse Contrast Enhancement.Cureus · 2024Article
- Prevalence and prognosis of hypoxia-inducible factor-2α (HIF-2α) pathway gene mutations across advanced solid tumors.Cancer medicine · 2024Observational
- A comparative analysis of surgically excised hereditary and sporadic pheochromocytomas: Insights from a single-center experience.The Kaohsiung journal of medical sciences · 2024Article
- Somatic Mutation Profiling in Head and Neck Paragangliomas.The Journal of clinical endocrinology and metabolism · 2022Article
- Review
- Adrenal pheochromocytoma: is it all or the tip of the iceberg?Japanese journal of radiology · 2022Review
- Review
- HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models.Cancers · 2021Article
- Metabolic rivalry: circadian homeostasis and tumorigenesis.Nature reviews. Cancer · 2020Review
- A narrative review of the role of fibroblasts in the growth and development of neurogenic tumors.Annals of translational medicine · 2020Review
- Mutation profiling in eight cases of vagal paragangliomas.BMC medical genomics · 2020Article
- Multiple paragangliomas: a case report.BMC medical genomics · 2020Article
- Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations.Endocrine pathology · 2019Article
- A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.Neoplasma · 2019Review
- Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin.Cancers · 2019Review
- Medical genetics studies at BGRS conference series.BMC medical genetics · 2019Article
- Mutational load in carotid body tumor.BMC medical genomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paragangliomas/pheochromocytomas comprise rare tumors that arise from the extra-adrenal paraganglia, with an incidence of about 2 to 8 per million people each year. Approximately 40% of cases are due to genetic mutations in at least one out of more than 30 causative genes. About 25-30% of pheochromocytomas/paragangliomas develop under the conditions of a hereditary tumor syndrome a third of which are caused by mutations in the VHL gene. Together, the gene mutations in this disorder have implicated multiple processes including signaling pathways, translation initiation, hypoxia regulation, protein synthesis, differentiation, survival, proliferation, and cell growth. The present review contemplates the mutations associated with the development of pheochromocytomas/paragangliomas and their potential to serve as specific markers of these tumors and their progression. These data will improve our understanding of the pathogenesis of these tumors and likely reveal certain features that may be useful for early diagnostics, malignancy prognostics, and the determination of new targets for disease therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.